Clinical trial · Observational
Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease
Title: Evaluation of Systemic IDO Levels After Various Immunotherapeutics
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): slow accrual
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood from patients with cancer, hepatitis C, or Crohn disease in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer and other diseases. PURPOSE: This laboratory study is looking at the effect of biological therapy on biomarkers in patients with untreated hepatitis C, metastatic melanoma, or Crohn disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| high performance liquid chromatography | Other | — | UNRESOLVED |
| infliximab | Biological | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| pegylated interferon alfa | Biological | — | UNRESOLVED |
| ribavirin | Drug | — | UNRESOLVED |
| ticilimumab | Biological | Tremelimumab | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Systemic indoleamine 2, 3 dioxygenase levels in tissue at baseline and 3 to 4 weeks after treatment is initiated (timepoints for cancer and hepatitis patients)
- timeFrame
- at baseline and 3 to 4 weeks after treatment is initiated
- measure
- Serum TRP levels at baseline and at 3 to 4 weeks after treatment is initiated (timepoints for cancer and hepatitis patients)
- timeFrame
- at baseline and at 3 to 4 weeks after treatment is initiated
- measure
- Serum KYN levels at baseline and at 3 to 4 weeks after treatment is initiated (timepoints for cancer and hepatitis patients)
- timeFrame
- at baseline and at 3 to 4 weeks after treatment is initiated
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria:
DISEASE CHARACTERISTICS:
* Diagnosis of 1 of the following:
* Acute or chronic hepatitis C
* Receiving pegylated interferon alfa and ribavirin
* Metastatic melanoma
* Receiving ticilimumab
* Crohn disease
* Received prior infliximab
Exclusion Criteria:
* Not specified
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* See Disease CharacteristicsReferences
Publications (0)
Data not yet available